Physician profile
Otis D Wright
NPI 1104909688
$3,833.91
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,656 · 2022: $1,673 · 2023: $389 · 2024: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $504.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $426.82 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.19 | 2021-2022 | |
| Novo Nordisk INC | $326.34 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $260.67 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $254.82 | 2023-2024 | Austedo Xr |
| Astrazeneca Pharmaceuticals Lp | $240.76 | 2021-2022 | |
| Glaxosmithkline, LLC. | $234.68 | 2021-2022 | |
| Esperion Therapeutics, INC. | $188.40 | 2021-2022 | |
| Lilly USA, LLC | $161.35 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $143.44 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $140.26 | 2022-2023 | Rexulti |
| Merck Sharp & Dohme LLC | $129.51 | 2022-2023 | Verquvo, Belsomra |
| Corcept Therapeutics | $119.22 | 2022-2023 | Korlym |
| Medtronic, INC. | $78.93 | 2022 | |
| Amgen INC. | $71.43 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $63.50 | 2022 | |
| Sanofi-Aventis U.S. LLC | $54.82 | 2022 | |
| Mylan Specialty L.P. | $48.66 | 2021 | |
| Daiichi Sankyo INC. | $47.27 | 2021 | |
| Amarin Pharma, INC. | $47.07 | 2021 | |
| Dexcom, INC. | $44.59 | 2021 | |
| Clarus Therapeutics INC. | $42.43 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.21 | 2021 | |
| Mannkind Corporation | $40.92 | 2022 | |
| Stryker Corporation | $29.40 | 2022 | |
| Boston Scientific Corporation | $28.61 | 2022 | |
| Vision Quest Industries INC. | $28.55 | 2023 | |
| Ironwood Pharmaceuticals, INC | $27.76 | 2021 | |
| Idorsia Pharmaceuticals US INC | $24.97 | 2023 | Quviviq |
| Genzyme Corporation | $21.14 | 2021 | |
| Astellas Pharma US INC | $19.14 | 2021 | |
| Optos, INC. | $18.32 | 2021 | |
| Optinose US, INC. | $17.84 | 2021 | |
| Lundbeck LLC | $16.08 | 2023 | Rexulti |
| Evoke Pharma, INC. | $15.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Otis Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.